

Key Terms of CEO/Managing Director Employment Contract

Melbourne, Australia, 25 November 2019: [Sienna Cancer Diagnostics Ltd \(ASX: SDX\)](#) (“Sienna” or “the Company”), a medical technology company developing and commercialising innovative In-Vitro Diagnostic (IVD) tests, announced the appointment of Mr Carl Stubbings to the position of CEO/Managing Director on 16 October 2019. The final terms of Carl’s employment contract have now been agreed and an employment contract executed. The key terms of the contract are:

Fixed Remuneration: \$326,705

Superannuation: The required percentage of fixed remuneration, currently 9.5%, up to the maximum superannuation contributions base in accordance with the Company’s obligations under the Superannuation Guarantee (Administration) Act 1992.

Short Term Incentive: Up to 20% of base salary per annum, in cash, subject to the achievement of Board defined corporate goals that drive shareholder value.

Long Term Incentive: 2,900,000 share options, issued under the Company’s Employee Share Options Plan (ESOP) with an exercise price of 5.3 cents, calculated at a 25% premium to the 30-day Volume Weighted Average Price (VWAP) of Sienna’s ordinary shares at the execution date of the employment contract. These options will vest in 3 equal tranches:

- one-third vesting 12 months from the execution of the employment contract; and
- one-third vesting 24 months from the execution of the employment contract; and
- one-third vesting 36 months from the execution of the employment contract.

All options will expire 5 years after the issue date.

These options will require shareholder approval at the next meeting of members.

Termination & Notice: The employment contract may be terminated by the Company or the employee by either party providing three (3) months written notice.

ENDS

For further information, please contact:

Geoff Cumming, Chairman
Sienna Cancer Diagnostics Ltd
gcumming@siennadiagnostics.com.au
+61 3 8288 2141



About Sienna Cancer Diagnostics

Sienna Cancer Diagnostics Ltd is an Australian medical technology company with operations in the United States, Europe, Asia, Latin America and Australia. Sienna's strengths lie in the identification, development and commercialisation of novel IVD technologies that satisfy an unmet clinical / market need. The Company has taken its first product, an IVD test for the biomarker hTERT, from research, through development, manufacturing, product registration, and market launch through a growing network of distribution partners.

The Company is focused on growing revenues from the existing product, increasing market access through new distribution partners, extending the applications for their hTERT test, and expanding their product offerings with the addition of new technologies into the product development pipeline.

Sienna's most recent technology acquisition was a unique technology for the capture and isolation of target analytes in liquid biopsy samples. The sample preparation technology, known as SIEN-NET™, can more accurately and rapidly prepare samples for the liquid biopsy testing of a range of clinically useful biomarkers including exosomes, lipids, proteins, and other molecular targets of interest.

Forward Looking Statements

This announcement may contain forward-looking statements, which include all matters that are not historical facts. These forward-looking statements speak only as at the date of this announcement. These statements, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by forward-looking statements. Without limitation, indications of, and guidance on, future earnings and financial position and performance are examples of forward-looking statements. No representation, warranty or assurance (express or implied) is given or made by Sienna that the forward-looking statements contained in this announcement are accurate, complete, reliable, or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, each of Sienna, its related companies and their respective directors, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward-looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.

